SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Merck Says Sac-TMT Trial Met Overall Survival Endpoint

Merck said its TroFuse-015 trial found sacituzumab tirumotecan improved overall survival versus physician’s choice in third-line or later gastroesophageal adenocarcinoma.

MRK

Related stories